Related Experiment Videos
Treatment of aplastic anemia in children with recombinant human granulocyte colony-stimulating factor
S Kojima1, M Fukuda, Y Miyajima
1Division of Hematology/Oncology, Children's Medical Center, Japanese Red Cross Nagoya First Hospital.
Insights
Recombinant human granulocyte colony-stimulating factor (rhG-CSF) effectively boosted neutrophil counts in children with aplastic anemia. This treatment shows promise for managing infections in these patients.
Area of Science:
- Pediatric Hematology
- Oncology
- Immunology
Background:
- Aplastic anemia is a serious condition characterized by bone marrow failure.
- Neutropenia, a common complication, increases susceptibility to infections.
- Growth factors are being explored to manage bone marrow failure disorders.
Purpose of the Study:
- To evaluate the efficacy and safety of recombinant human granulocyte colony-stimulating factor (rhG-CSF) in children with aplastic anemia.
- To assess the impact of rhG-CSF on neutrophil counts and myeloid precursor differentiation.
- To determine the potential role of rhG-CSF in managing infections in pediatric aplastic anemia.
Main Methods:
- Twenty children with aplastic anemia received rhG-CSF (400 mcg/m2/day IV for 2 weeks).
- Dose escalation was performed for non-responders (800-1200 mcg/m2/day).
- Neutrophil counts, differential counts, and bone marrow aspirates were analyzed.
Main Results:
- Neutrophil counts increased 2.7- to 28.0-fold in 12 of 20 patients.
- Three of five non-responders showed increased neutrophils after dose escalation.
- Bone marrow myeloid/erythroid ratio increased; response was transient.
Conclusions:
- rhG-CSF effectively stimulates granulopoiesis in pediatric aplastic anemia.
- The agent is potentially useful for managing infections in these patients.
- No severe toxicity was observed, suggesting a favorable safety profile.
Abstract:
Twenty children (aged 1 to 17 years) with severe or moderate aplastic anemia were treated with recombinant human granulocyte colony-stimulating factor (rhG-CSF) at a dose of 400 micrograms/m2 per day administered as a 30-minute intravenous (IV) infusion daily for 2 weeks. This treatment increased the neutrophil counts (2.7- to 28.0-fold) in 12 of the 20 patients. Increasing doses (800 or 1,200 micrograms/m2 per day) were administered to five patients who had not responded to the initial dose, and three showed an increase in neutrophil count. Differential counts of bone marrow (BM) aspirates showed an increase in the myeloid/erythroid ratio. The response was transient, however, and the neutrophil count returned to baseline within 2 to 10 days of discontinuing treatment. No severe toxicity attributable to rhG-CSF was observed. The results suggest that this agent is effective in stimulating granulopoiesis in children with aplastic anemia. Our study also indicates that rhG-CSF will be particularly useful in managing patients with aplastic anemia complicated by bacterial or fungal infection.